Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELDTM) and BBV152 (COVAXIN?): a non-inferiority phase 4, participant and observer-blinded, randomised study
The Lancet regional health. Southeast Asia（2023）
关键词
COVID-19,Vaccine trial,Homologous booster,Heterologous booster,ChAdOx1 nCov-19,COVISHIELD,BBV152,Covaxin,Immunogenicity,Safety
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要